The US Food and Drug Administration (FDA) has approved ProStrakan Group’s Sancuso®, ProStrakan’s novel, patented trans-dermal patch used to prevent chemotherapy-induced nausea and vomiting (CINV). Sancuso emerges as a patient-friendly treatment option which is both non-oral and non- invasive. The company hopes to launch the product in the United States by the end of the year 2008. It will be ProStrakan’s first ever product launch in the country.